OBJECTIVES: Migraine is a public health problem that has an impact on both the individual sufferer and on society. The objective of this study was to examine the PCS (physical component summary) and MCS (mental component summary) score after being treated with one of the two different recommended level A medications – Triptans and Anti-epileptics. METHODS: MEPS data 2003-2010 (with panel 9-14) were downloaded from the AHRQ website. Migraine patients who started to receive either Triptans or Anti-epileptics in round 3 were retained in the cohort. Patients who received combination therapy or received the medication in round 1 or 2 were excluded in order to control for the baseline characteristics. Propensity score method was used to ensure the patients being compared are equal within each tertile. The predicted probability of receiving Triptans was calculated for all patients in the cohort by using multiple logistic regression to control for demographics, comorbidity and PCS/MCS in round 2. The probabilities were then stratified into tertiles. The outcomes – PCS and MCS in round 4 were compared within each tertile to examine if there were any differences between the two medications. RESULTS: Overall there were 120 patients in the cohort with weighted frequency of 2,779,074 (2,049,642 for Triptans and 729,432 for Anti-epileptics). After the propensity score stratification, all the baseline information between the two treatment cohorts were equal in each tertile except race in tertile 2 (p=0.0124). After the outcomes comparison, there were no differences in round 4 PCS and MCS score between the two medications for all three tertiles. CONCLUSIONS: Triptans are the most expensive among all the migraine medications. However, the findings of our study demonstrated there were no differences in PCS and MCS after the treatment. Future studies should examine different outcomes and see if Triptans can improve other clinical findings.